2Seventy Bio Inc (TSVT) - Total Assets
Based on the latest financial reports, 2Seventy Bio Inc (TSVT) holds total assets worth $480.00 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 2Seventy Bio Inc book value and equity for net asset value and shareholders' equity analysis.
2Seventy Bio Inc - Total Assets Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's total assets have evolved over time, based on quarterly financial data.
2Seventy Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
2Seventy Bio Inc's total assets of $480.00 Million consist of 39.1% current assets and 61.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.9% |
| Accounts Receivable | $7.78 Million | 1.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.88 Million | 1.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of 2Seventy Bio Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 2Seventy Bio Inc's current assets represent 39.1% of total assets in 2024, an increase from 6.6% in 2019.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2024, up from -42.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
2Seventy Bio Inc Competitors by Total Assets
Key competitors of 2Seventy Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
2Seventy Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.80 | 3.52 | 0.18 |
| Quick Ratio | 4.80 | 3.72 | 0.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $157.19 Million | $152.44 Million | $-85.16 Million |
2Seventy Bio Inc - Advanced Valuation Insights
This section examines the relationship between 2Seventy Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | -15.2% |
| Total Assets | $479.51 Million |
| Market Capitalization | $266.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values 2Seventy Bio Inc's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 2Seventy Bio Inc's assets decreased by 15.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 2Seventy Bio Inc (2019–2024)
The table below shows the annual total assets of 2Seventy Bio Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $479.51 Million | -15.19% |
| 2023-12-31 | $565.43 Million | -13.89% |
| 2022-12-31 | $656.66 Million | -13.56% |
| 2021-12-31 | $759.67 Million | +143.00% |
| 2020-12-31 | $312.62 Million | -0.74% |
| 2019-12-31 | $314.95 Million | -- |
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more